Diaceutics PLC
Symbool: DIUXF
PNK
1.3672
USDMarktprijs vandaag
-124.8659
Koers/Winst Verhouding
2.7906
Koers/Winst Groei Verhouding
123.70M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Diaceutics PLC (DIUXF) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 19.8 | 19.7 | 25.3 | |||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.net-receivables | 0 | 10.4 | 10 | 7.8 | |||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-current-assets | 0 | 0.6 | 0.4 | 0.6 | |||||||
balance-sheet.row.total-current-assets | 0 | 30.9 | 30.1 | 33.6 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2.1 | 2.1 | 0.2 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.long-term-investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0.3 | |||||||
balance-sheet.row.other-non-current-assets | 0 | -17.1 | -14.7 | -9.2 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 17.4 | 15 | 9.9 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.account-payables | 0 | 0.8 | 0.5 | 0.5 | |||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.3 | 0.1 | |||||||
balance-sheet.row.tax-payables | 0 | 0.4 | 0.3 | 0.8 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 1.2 | 1.3 | 0 | |||||||
Deferred Revenue Non Current | 0 | 0 | -0.4 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1.6 | 2 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2 | 1.7 | 0.4 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 1.4 | 0 | |||||||
balance-sheet.row.total-liab | 0 | 5.7 | 4.4 | 3.3 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.3 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||
balance-sheet.row.retained-earnings | 0 | 5.3 | 4.1 | 3.2 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -0.3 | 0 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 36.9 | 36.4 | 36.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.total-debt | 0 | 1.3 | 1.6 | 0.1 | |||||||
balance-sheet.row.net-debt | 0 | -18.5 | -18.1 | -25.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0.6 | 0.5 | -0.7 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 1.3 | -0.5 | -0.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0.5 | 0.4 | 0.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -0.3 | -1.7 | 0.5 | |||||||
cash-flows.row.account-receivables | 0 | -1.6 | -1.5 | 0.5 | |||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.account-payables | 0 | 1.3 | -0.2 | -0.1 | |||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0.1 | 0 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-investing-activites | 0 | 0.1 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4.8 | -5.6 | -6.3 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0 | 19.6 | |||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -0.2 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -0.2 | -0.3 | 19.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||
cash-flows.row.net-change-in-cash | 0 | 0.2 | -5.6 | 13.5 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19.8 | 19.7 | 25.3 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 19.7 | 25.3 | 11.7 | |||||||
cash-flows.row.operating-cash-flow | 0 | 5.1 | 0.6 | 0.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.free-cash-flow | 0 | 0.2 | -5 | -6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 19.5 | 13.9 | 12.7 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 2.8 | 3.2 | 3.2 | |||||||
income-statement-row.row.gross-profit | 0 | 16.7 | 10.7 | 9.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.operating-expenses | 0 | 16.2 | 10.2 | 9.7 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 18.9 | 13.4 | 13 | |||||||
income-statement-row.row.interest-income | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 0.6 | 0.6 | -0.7 | |||||||
income-statement-row.row.income-before-tax | 0 | 0.6 | 0.5 | -0.7 | |||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | -0.1 | -0.9 | |||||||
income-statement-row.row.net-income | 0 | 0.7 | 0.6 | 0.3 |
Vaak gestelde vragen
Wat is Diaceutics PLC (DIUXF) totale activa?
Diaceutics PLC (DIUXF) totale activa is 48256000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.796.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.027.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.061.
Wat is Diaceutics PLC (DIUXF) nettowinst (netto-inkomen)?
De nettowinst is 724000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1329000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 16166000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.